Academic Unit of Population and Lifespan Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
Neonatal Department, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Arch Dis Child Fetal Neonatal Ed. 2022 Mar;107(2):150-155. doi: 10.1136/archdischild-2021-322390. Epub 2021 Aug 19.
To determine the change in non-invasive ventilation (NIV) use over time in infants born at <32 weeks' gestation and the associated clinical outcomes.
Retrospective cohort study using routinely recorded data from the National Neonatal Research Database of infants born at <32 weeks admitted to neonatal units in England and Wales from 2010 to 2017.
In 56 537 infants, NIV use increased significantly between 2010 and 2017 (continuous positive airway pressure (CPAP) from 68.5% to 80.2% in 2017 and high flow nasal cannula (HFNC) from 14% to 68%, respectively) (p<0.001)). Use of NIV as the initial mode of respiratory support also increased (CPAP, 21.5%-28.0%; HFNC, 1%-7% (p<0.001)).HFNC was used earlier, and for longer, in those who received CPAP or mechanical ventilation. HFNC use was associated with decreased odds of death before discharge (adjusted OR (aOR) 0.19, 95% CI 0.17 to 0.22). Infants receiving CPAP but no HFNC died at an earlier median chronological age: CPAP group, 22 (IQR 10-39) days; HFNC group 40 (20-76) days (p<0.001). Among survivors, HFNC use was associated with increased odds of bronchopulmonary dysplasia (BPD) (aOR 2.98, 95% CI 2.81 to 3.15) and other adverse outcomes.
NIV use is increasing, particularly as initial respiratory support. HFNC use has increased significantly with a sevenfold increase soon after birth which was associated with higher rates of BPD. As more infants survive with BPD, we need robust clinical evidence, to improve outcomes with the use of NIV as initial and ongoing respiratory support.
确定在 32 周以下早产儿中,随着时间的推移,无创通气(NIV)的使用变化以及相关的临床结局。
使用英国和威尔士新生儿单位常规记录的数据,对 2010 年至 2017 年期间出生于<32 周的婴儿进行回顾性队列研究。
在 56537 名婴儿中,NIV 的使用在 2010 年至 2017 年间显著增加(持续气道正压通气(CPAP)从 2017 年的 68.5%增加到 80.2%,高流量鼻导管(HFNC)从 14%增加到 68%,分别)(p<0.001))。作为初始呼吸支持模式的 NIV 使用也有所增加(CPAP,21.5%-28.0%;HFNC,1%-7%(p<0.001))。HFNC 在接受 CPAP 或机械通气的患者中更早使用,且使用时间更长。HFNC 的使用与出院前死亡的几率降低相关(调整后的比值比(aOR)0.19,95%CI 0.17 至 0.22)。接受 CPAP 但未接受 HFNC 的婴儿在较早的年龄死亡:CPAP 组 22(IQR 10-39)天;HFNC 组 40(20-76)天(p<0.001)。在幸存者中,HFNC 的使用与支气管肺发育不良(BPD)的几率增加相关(aOR 2.98,95%CI 2.81 至 3.15)和其他不良结局。
NIV 的使用正在增加,特别是作为初始呼吸支持。HFNC 的使用显著增加,出生后不久增加了七倍,与更高的 BPD 发生率相关。随着越来越多的 BPD 婴儿存活,我们需要有可靠的临床证据,以改善使用 NIV 作为初始和持续呼吸支持的效果。